Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

Status unconfirmed · Not applicable

Conditions studied: Asthma, Allergic Rhinitis

In brief

Double blind protocol treatment of 2/3 of the patients with omalizumab and 1/3 placebo administer for 4 months. Patients selected for the study must have both aspirin exacerbated respiratory disease and allergic asthma and rhinitis. They must also have completed aspirin desensitization and be taking aspirin on a daily basis for the treatment of AERD.

Key facts

Study ID

NCT00286416

Run by

Scripps Clinic

People needed

60

Starts

2006-01-01

Expected to finish

2008-07-01

Last updated by the study team

2006-11-07

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• aspirin exacerbated respiratory disease and allergic asthma

You may not qualify if…

• pregnant females,starting immunotherapy in the past 3 months, prior treatment with Xolair, negative allergy skin tests,unable to participate in lung function tests, unable to complete data forms,low platelets, serum IGE greater than 700 iu,cancer,another uncontrolled medical condition, unacceptable concomitant medication, under the age of 18 years.

Where it is running

• Scripps Clinic at Torrey Pines — La Jolla, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.